Sartorius/€SRT3

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sartorius

Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.

Ticker

€SRT3
Sector

Primary listing

XETRA

Employees

13,685

Sartorius Metrics

BasicAdvanced
€14B
-
-
1.24
€0.74
0.33%

What the Analysts think about Sartorius

Analyst ratings (Buy, Hold, Sell) for Sartorius stock.

Bulls say / Bears say

Bioprocess Solutions division sales rose 8.8% in constant currencies in H1 2025, driven by high-margin consumables, and the segment’s underlying EBITDA margin expanded to 31.6% on volume and mix benefits (Sartorius IR).
Group underlying EBITDA grew 11.9% to €527 million in H1 2025, with the margin improving to 29.8%, demonstrating operational efficiency and economies of scale (Sartorius IR).
Management reconfirmed full-year 2025 guidance for ~6% organic sales growth and a group underlying EBITDA margin of 29–30%, underscoring confidence in market resilience and execution (Sartorius IR).
Lab Products & Services division sales fell 4.0% in constant currencies in H1 2025, with underlying EBITDA margin contracting to 22.3%, reflecting persistent weakness in lab‐instrument demand (Sartorius IR).
Group Q2 2025 revenue of €884 million missed consensus by 1%, causing Sartorius shares to slide over 6% in European trading, highlighting sensitivity to minor sales shortfalls (Investing.com).
The rolling 12-month book-to-bill ratio eased to “above 1” in Q2 from “well above 1” in Q1, suggesting a moderation in order intake momentum despite remaining above the critical threshold (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

Sartorius Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sartorius Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT3

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs